SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Amgen Says Dazodalibep Regimens Meet Week 48 Primary Endpoint

Amgen said dazodalibep regimens met the primary endpoint at week 48, with significant disease activity reduction.

AMGN

Related stories